Simon Westbrook

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom.

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge.

Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom.

Moximed, Inc. develops minimally invasive, joint sparing solutions for patients with knee osteoarthritis. Its Osteoarthritis treatment can minimize joint pain, restore normal activity levels, and slow down disease progression. The company was founded by Anton G. Clifford in 2006 and is headquartered in Hayward, CA.

STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.

Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.

Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany.

Methuselah Health UK Ltd. develops platforms for the detection of major diseases for middle and old age people. The company was founded by David John Grainger in 2015 and is headquartered in Babraham, the United Kingdom.

Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom.

Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom.

UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom.

Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom.

SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.

Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom.

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.

Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands.

Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The company is based in Cambridge, UK and was founded in 2016.

F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.

Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland.

Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland.

SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

Part of Pfizer Inc., Pfizer Holdings International Luxembourg (PHIL) SARL is an investment holding company. The company is based in Luxembourg, Luxembourg.